Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion type Assertion NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_head.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion description "[The high incidence of CRF(1) or CRF(2) receptors in selected human tumors suggests that unlabeled CRF agonists may be evaluated as inhibitors of tumor cell proliferation in cancer therapy, and radiolabeled CRF analogs may be used for cancer diagnosis and/or radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_provenance.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion evidence source_evidence_literature NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_provenance.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion SIO_000772 12843181 NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_provenance.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion wasDerivedFrom befree-20150227 NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_provenance.
- NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_assertion wasGeneratedBy ECO_0000203 NP326162.RAKkWAG57TjDRHFQZXywdD4s-W2Cx4zQEX48-Ec0M7iLs130_provenance.